RNA, U1 small nuclear 108, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-108P profile across patient tissues and cancer cell-line models. RNU1-108P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU1-108P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RNU1-108P RNA expression shows 6,638 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where RNU1-108P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-108P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-108P survival associations across molecular data types. RNU1-108P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-108P RNA expression–survival associations across cancer types. High RNU1-108P expression shows unfavorable associations in KIRC, ACC, LUAD, LIHC and LGG, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU1-108P RNA expression.
This table summarizes RNU1-108P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-108P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-108P shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD. The KIRC box plot shows higher RNU1-108P RNA expression in normal versus tumor tissue (log2 FC = −0.088, t-test p = .015).
This table shows molecular features associated with RNU1-108P in patient tissues and cancer cell lines. In patient samples, RNU1-108P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
